Summit Therapeutics Plc Stock Market Value
| SMMT Stock | USD 16.15 0.47 3.00% |
| Symbol | Summit |
Is there potential for Biotechnology market expansion? Will Summit introduce new products? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Summit Therapeutics PLC's market price often diverges from its book value, the accounting figure shown on Summit's balance sheet. Smart investors calculate Summit Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Summit Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Summit Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Summit Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Summit Therapeutics.
| 11/29/2025 |
| 02/27/2026 |
If you would invest 0.00 in Summit Therapeutics on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding Summit Therapeutics PLC or generate 0.0% return on investment in Summit Therapeutics over 90 days. Summit Therapeutics is related to or competes with Roivant Sciences, BridgeBio Pharma, Revolution Medicines, Ascendis Pharma, Ionis Pharmaceuticals, EXACT Sciences, and Royalty Pharma. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infect... More
Summit Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Summit Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Summit Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 23.61 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.49 |
Summit Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Summit Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Summit Therapeutics' standard deviation. In reality, there are many statistical measures that can use Summit Therapeutics historical prices to predict the future Summit Therapeutics' volatility.| Risk Adjusted Performance | 0.0057 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.13) |
Summit Therapeutics February 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0057 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 2.64 | |||
| Coefficient Of Variation | (32,604) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.3 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.58) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 23.61 | |||
| Value At Risk | (5.75) | |||
| Potential Upside | 6.49 | |||
| Skewness | (0.25) | |||
| Kurtosis | 2.26 |
Summit Therapeutics PLC Backtested Returns
Summit Therapeutics PLC owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0247, which indicates the firm had a -0.0247 % return per unit of risk over the last 3 months. Summit Therapeutics PLC exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Summit Therapeutics' Risk Adjusted Performance of 0.0057, coefficient of variation of (32,604), and Variance of 14.3 to confirm the risk estimate we provide. The entity has a beta of 0.17, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Summit Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Summit Therapeutics is expected to be smaller as well. At this point, Summit Therapeutics PLC has a negative expected return of -0.0914%. Please make sure to validate Summit Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Summit Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.15 |
Insignificant predictability
Summit Therapeutics PLC has insignificant predictability. Overlapping area represents the amount of predictability between Summit Therapeutics time series from 29th of November 2025 to 13th of January 2026 and 13th of January 2026 to 27th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Summit Therapeutics PLC price movement. The serial correlation of 0.15 indicates that less than 15.0% of current Summit Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.15 | |
| Spearman Rank Test | -0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.97 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.